About

Mitochon Pharmaceuticals is a clinical staged biotech company, that focuses on developing drugs that target the mitochondria for a host of serious diseases with significant unmet medical needs. Our development programs are primarily focused on time sensitive insidious neurodegenerative & neuromuscular diseases including: Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease (HD), Progressive forms of Multiple Sclerosis (SPMS & PPMS), Traumatic Brain Injury (TBI), Alzheimer’s Disease (AD), and Parkinson Disease (PD). Although they appear as separate indications, on-going research has linked these diseases to a common theme, mitochondria dysfunction. By correcting these dysfunctions, Mitochon aims to open the door for a broad range of disease modifying therapies. Mitochon is led by a team of industry executives with over 100-years of combined experience and a passion to bring forward breakthrough drug therapies for a host of insidious diseases.